Alligator Bioscience to address immunogenicity with Epibase

10-Oct-2006

Alligator Bioscience AB and AlgoNomics NV announced that they have entered into a collaboration. AlgoNomics will employ its Epibase® platform to complement Alligator Bioscience in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers. The collaboration shall allow Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with their proprietary ssDNA recombination technology FIND®.

"All proteins delivered as biopharmaceuticals could render an immune response. For Alligator it is of great importance to make a responsible risk assessment on any new project. We are therefore grateful to be able to work with AlgoNomics, delivering a state of the art technology, for investigating the theoretical consequence of an immune response", stated Dr. Gun-Britt Fransson, CEO of Alligator Bioscience.

Financial terms and the therapeutic focus of the collaboration were not disclosed.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...